Daniel Margolis, MD, Author at Grand Rounds in Urology

Daniel Margolis, MD

Weill Cornell Medical College

New York, New York

Daniel Margolis, MD, is an Associate Professor of Radiology at Weill Cornell Medicine in New York City. He is a graduate of the University of California, Berkeley, and earned his MD from the University of Southern California in Los Angeles. After a transitional year-long internship with the Los Angeles VA Healthcare System, he completed a residency in Diagnostic Radiology at the University of California, Los Angeles. Dr. Margolis completed a Fellowship in Advanced Imaging at Stanford University Medical Center and the K30 Graduate Training Program in Translational Investigation at UCLA. He has 90+ publications regarding using MRI for detecting and characterizing prostate cancer. He serves on the American College of Radiology Prostate Imaging Reporting and Data Systems Committee and is Co-Chair of the Society of Abdominal Radiology Prostate Cancer Disease-Focused Panel.

Talks by Daniel Margolis, MD

Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-up – Creating Imaging Based Short and Intermediate Outcomes

Posted by Daniel Margolis, MD | Jun 2024

Daniel Margolis, MD, focuses on standardized MRI and molecular imaging reporting for follow-up in prostate cancer focal therapy. Implementing standardized protocols for imaging evaluation post-focal therapy aims to ensure consistency and reliability across different healthcare settings, facilitate accurate comparison of treatment outcomes, and enable evidence-based decision-making.
Multiparametric MRI (mpMRI) is a cornerstone of the follow-up strategy. By utilizing standardized reporting systems such as the Prostate Imaging Reporting and Data System (PI-RADS), radiologists can systematically assess post-treatment changes, detect residual or recurrent disease, and monitor treatment response. Dr. Margolis also discusses molecular imaging techniques that offer additional insights into treatment response and disease activity at a molecular level. Novel tracers and imaging agents target specific biological markers associated with prostate cancer, enhancing the precision and sensitivity of post-treatment assessments.
Dr. Margolis emphasizes the importance of integrating these imaging modalities into a cohesive framework. This approach not only aids in the early detection of treatment failure or disease recurrence but also guides timely intervention and adjustment of therapeutic strategies.

Image-Guided Biopsy and Treatment

Posted by Daniel Margolis, MD | Jan 2020

Daniel Margolis, MD, discusses the evolving role of imaging in biopsy and focal therapy guidance. He reviews the advantages of current image-targeting techniques, including MRI/ultrasound fusion and MRI in-bore targeting.